Who Paid My Doc
Simon Patton
Urogynecology and Reconstructive Pelvic Surgery Wichita, KS Medical Doctor
NPI 1497042444 CMS profile 975311
1515 S Clifton Ave Ste 400, Wichita, KS 67218
General payments
$1,491
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Simon Patton of Wichita, KS is reported in the CMS Open Payments database as having received $1,491 across 73 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 29th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $128 | 4 | |
| 2024 | General | $100 | 3 | |
| 2023 | General | $249 | 32 | |
| 2022 | General | $183 | 9 | |
| 2021 | General | $634 | 12 | |
| 2019 | General | $196 | 13 |
Beside peers
- Simon Patton
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Simon Patton were reported at $128. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.
Show as a table
| Year | Simon Patton | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $196 | $358 | $132–$1,270 | $163 |
| 2020 | $0 | $198 | $86–$642 | $114 |
| 2021 | $634 | $361 | $118–$1,182 | $132 |
| 2022 | $183 | $410 | $128–$1,175 | $149 |
| 2023 | $249 | $434 | $152–$1,344 | $160 |
| 2024 | $100 | $494 | $193–$1,331 | $164 |
| 2025 | $128 | $412 | $133–$1,300 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,486
Drug cost
$399,759
Branded share of claims
62.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 338 | $246,835 | |
| Myrbetriq Mirabegron | Brand | 206 | $128,344 | |
| Estradiol | Generic | 152 | $9,663 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 223 | $4,438 | |
| Clobetasol Propionate | Generic | 32 | $2,656 | |
| Solifenacin Succinate | Generic | 84 | $2,592 | |
| Trimethoprim | Generic | 34 | $1,891 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 96 | $1,620 | |
| Cephalexin | Generic | 61 | $250 | |
| Loperamide Loperamide Hcl | Brand | 12 | $239 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 38 billing codesPaid by Medicare
$137,028
Medicare patients
305
Services billed
4,821
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 72% | |
| Arthritis | 47% | |
| Diabetes | 29% | |
| Depression | 28% | |
| Osteoporosis | 20% | |
| Ischemic heart disease | 19% | |
| Chronic kidney disease | 16% | |
| Atrial fibrillation | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, onabotulinumtoxina, 1 unit J0585 | Office | 26 | 4,100 | $20,450 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
73 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in Kansas
Charles Butrick
Urogynecology and Reconstructive Pelvic Surgery · Overland Park, KS
Cathy Dahl
Urogynecology and Reconstructive Pelvic Surgery · Lawrence, KS
Erika Hunter
Urogynecology and Reconstructive Pelvic Surgery · Overland Park, KS
Patrick Nosti
Urogynecology and Reconstructive Pelvic Surgery · Overland Park, KS
Trang Pham
Urogynecology and Reconstructive Pelvic Surgery · Wichita, KS
Abby Stork
Urogynecology and Reconstructive Pelvic Surgery · Overland Park, KS
Related records
Urogynecology and Reconstructive Pelvic Surgery in Kansas
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Kansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.